Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice

ASIA unversity > 醫學暨健康學院 > 生物科技學系 > 期刊論文 > Item 310904400/8269

請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/8269

題名:	Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice
作者:	Yiang, GT (Yiang, Giou-Teng);Harn, HJ (Harn, Horng-Jyh);Yu, YL (Yu, Yung-Luen);Hu, SC (Hu, Sheng-Chuan);Hung, YT (Hung, Yu-Ting);Hsieh, CJ (Hsieh, Chia-Jung);Lin, SZ (Lin, Shinn-Zong);Wei, CW (Wei, Chyou-Wei)
貢獻者:	Department of Biotechnology
關鍵詞:	RECOMBINANT ADENOASSOCIATED VIRUS;DIRECTED GENE-THERAPY;CANCER A549 CELLS;IN-VIVO;EFFICIENT TRANSDUCTION;TRANSGENE EXPRESSION;IMMUNOGENE THERAPY;IMMUNE-RESPONSE;DENDRITIC CELLS;PROTEIN-KINASE
日期:	2009-05
上傳時間:	2010-03-26 02:29:28 (UTC+0)
出版者:	Asia University
摘要:	Human interleukin-15 (hIL15) has anti-tumor activities, but it is not convenient for tumor treatment because of its short half-life. A gene therapy for mouse lung cancer using an adenovirus vector expressing IL15 has been reported. However, adenovirus vector-mediated gene therapy can provoke cellular toxicity and inflammatory reactions. The recombinant adenovirus-associated vector 2 (rAAV2) is safer due to minimal cellular toxicity and immune response. In order to demonstrate that gene therapy can be used safely and successfully for human cancer treatment, the rAAV2 expressing hIL15 gene (rAAV2-hIL15) is applied for human cervical cancer, HeLa cell, in this study. This study successfully demonstrates that rAAV2-hIL15 can express IL15 with bioactivities in vitro and in vivo. In conclusion, our studies show that human cervical cancers are inhibited on animal model with rAAV2-hIL15 treatment and provide a safer and important reference for human cancer gene therapy.
關聯:	JOURNAL OF BIOMEDICAL SCIENCE 16: Art. No. 47
顯示於類別:	[生物科技學系] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	436	檢視/開啟
164.doc		36Kb	Microsoft Word	289	檢視/開啟

在ASIAIR中所有的資料項目都受到原著作權保護.

資料載入中.....